Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Methoxyphenamine→

Methoxyphenamine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
93-30-1
Molecular formula
C11H17NO
Molecular weight
179.26 g/mol
Drug class
Sympathomimetic aminebeta-adrenergic bronchodilator and nasal decongestant
Mechanism of action
A phenethylamine derivative with sympathomimetic activity. It stimulates adrenergic pathways and produces bronchodilation through beta-adrenergic effects and vasoconstriction of nasal mucosal vessels through alpha-adrenergic effects; its selectivity is lower than modern inhaled beta-2 agonists.
Indications / reported uses
  • Historically used as a bronchodilator for reversible airway obstruction and as a nasal decongestant in selected combination products; current availability and product indications are jurisdiction-specific.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=methoxyphenamine · https://www.ncbi.nlm.nih.gov/mesh/?term=methoxyphenamine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Methoxyphenamine Environmental Risk Assessment (ERA) (the Methoxyphenamine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.